|
1
|
McInnes IB and Schett G: Cytokines in the
pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 7:429–442.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
McInnes IB and Schett G: The pathogenesis
of rheumatoid arthritis. N Engl J Med. 365:2205–2219. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Schett G, Elewaut D, McInnes IB, Dayer JM
and Neurath MF: How cytokine networks fuel inflammation: Toward a
cytokine-based disease taxonomy. Nat Med. 19:822–824. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kaneko Y and Takeuchi T: A paradigm shift
in rheumatoid arthritis over the past decade. Intern Med.
53:1895–1903. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hyrich KL, Watson KD, Silman AJ and
Symmons DP: British Society for Rheumatology Biologics Register:
Predictors of response to anti-TNF-alpha therapy among patients
with rheumatoid arthritis: Results from the British Society for
Rheumatology Biologics Register. Rheumatology (Oxford).
45:1558–1565. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Molenaar ET, Voskuyl AE, Dinant HJ,
Bezemer PD, Boers M and Dijkmans BA: Progression of radiologic
damage in patients with rheumatoid arthritis in clinical remission.
Arthritis Rheum. 50:36–42. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Picerno V, Ferro F, Adinolfi A, Valentini
E, Tani C and Alunno A: One year in review: The pathogenesis of
rheumatoid arthritis. Clin Exp Rheumatol. 33:551–558.
2015.PubMed/NCBI
|
|
8
|
Mateen S, Zafar A, Moin S, Khan AQ and
Zubair S: Under-standing the role of cytokines in the pathogenesis
of rheumatoid arthritis. Clin Chim Acta. 455:161–171. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kobayashi S, Momohara S, Kamatani N and
Okamoto H: Molecular aspects of rheumatoid arthritis: Role of
environmental factors. FEBS J. 275:4456–4462. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Luban S and Li ZG: Citrullinated peptide
and its relevance to rheumatoid arthritis: An update. Int J Rheum
Dis. 13:284–287. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tan EM and Smolen JS: Historical
observations contributing insights on etiopathogenesis of
rheumatoid arthritis and role of rheumatoid factor. J Exp Med.
213:1937–1950. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fearon U, Canavan M, Biniecka M and Veale
DJ: Hypoxia, mitochondrial dysfunction and synovial invasiveness in
rheumatoid arthritis. Nat Rev Rheumatol. 12:385–397. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mateen S, Moin S, Zafar A and Khan AQ:
Redox signaling in rheumatoid arthritis and the preventive role of
polyphenols. Clin Chim Acta. 463:4–10. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Khojah HM, Ahmed S, Abdel-Rahman MS and
Hamza AB: Reactive oxygen and nitrogen species in patients with
rheumatoid arthritis as potential biomarkers for disease activity
and the role of antioxidants. Free Radic Biol Med. 97:285–291.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kaneko S, Kondo Y, Yokosawa M and Sumida
T: Rheumatoid arthritis and cytokines. Nihon Rinsho. 74:913–918.
2016.(In Japanese). PubMed/NCBI
|
|
16
|
Nakayamada S, Kubo S, Iwata S and Tanaka
Y: Recent progress in JAK inhibitors for the treatment of
rheumatoid arthritis. BioDrugs. 30:407–419. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Schwartz DM, Bonelli M, Gadina M and
O'Shea JJ: Type I/II cytokines, JAKs, and new strategies for
treating autoimmune diseases. Nat Rev Rheumatol. 12:25–36. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rebar RW, Miyake A, Low TL and Goldstein
AL: Thymosin stimulates secretion of luteinizing hormone-releasing
factor. Science. 214:669–671. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Goodall GJ, Hempstead JL and Morgan JI:
Production and characterization of antibodies to thymosin beta 4. J
Immunol. 131:821–825. 1983.PubMed/NCBI
|
|
20
|
Hannappel E, Xu GJ, Morgan J, Hempstead J
and Horecker BL: Thymosin beta 4: A ubiquitous peptide in rat and
mouse tissues. Proc Natl Acad Sci USA. 79:2172–2175. 1982.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hannappel E and Leibold W: Biosynthesis
rates and content of thymosin beta 4 in cell lines. Arch Biochem
Biophys. 240:236–241. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sanders MC, Goldstein AL and Wang YL:
Thymosin beta 4 (Fx peptide) is a potent regulator of actin
polymerization in living cells. Proc Natl Acad Sci USA.
89:4678–4682. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dedova IV, Nikolaeva OP, Safer D, De La
Cruz EM and dos Remedios CG: Thymosin beta4 induces a
conformational change in actin monomers. Biophys J. 90:985–992.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Huff T, Rosorius O, Otto AM, Müller CS,
Ballweber E, Hannappel E and Mannherz HG: Nuclear localisation of
the G-actin sequestering peptide thymosin beta4. J Cell Sci.
117:5333–5341. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Malinda KM, Sidhu GS, Mani H, Banaudha K,
Maheshwari RK, Goldstein AL and Kleinman HK: Thymosin beta4
accelerates wound healing. J Invest Dermatol. 113:364–368. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Philp D, Huff T, Gho YS, Hannappel E and
Kleinman HK: The actin binding site on thymosin beta4 promotes
angiogenesis. FASEB J. 17:2103–2105. 2003.PubMed/NCBI
|
|
27
|
Chiu LL, Reis LA and Radisic M: Controlled
delivery of thymosin β4 for tissue engineering and cardiac
regenerative medicine. Ann N Y Acad Sci. 1269:16–25. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Smart N, Rossdeutsch A and Riley PR:
Thymosin beta4 and angiogenesis: Modes of action and therapeutic
potential. Angiogenesis. 10:229–241. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xiao Y, Chen Y, Wen J, Yan W, Zhou K and
Cai W: Thymosin β4: A potential molecular target for tumor therapy.
Crit Rev Eukaryot Gene Expr. 22:109–116. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jo JO, Kang YJ, Ock MS, Kleinman HK, Chang
HK and Cha HJ: Thymosin β4 expression in human tissues and in
tumors using tissue microarrays. Appl Immunohistochem Mol Morphol.
19:160–167. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yang H, Cui GB, Jiao XY, Wang J, Ju G and
You SW: Thymosin-beta4 attenuates ethanol-induced neurotoxicity in
cultured cerebral cortical astrocytes by inhibiting apoptosis. Cell
Mol Neurobiol. 30:149–160. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tapp H, Deepe R, Ingram JA, Yarmola EG,
Bubb MR, Hanley EN Jr and Gruber HE: Exogenous thymosin beta4
prevents apoptosis in human intervertebral annulus cells in vitro.
Biotech Histochem. 84:287–294. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Iguchi K, Usami Y, Hirano K, Hamatake M,
Shibata M and Ishida R: Decreased thymosin beta4 in apoptosis
induced by a variety of antitumor drugs. Biochem Pharmacol.
57:1105–1111. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wei C, Kumar S, Kim IK and Gupta S:
Thymosin beta 4 protects cardiomyocytes from oxidative stress by
targeting anti-oxidative enzymes and anti-apoptotic genes. PLoS
One. 7:e425862012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ho JH, Tseng KC, Ma WH, Chen KH, Lee OK
and Su Y: Thymosin beta-4 upregulates anti-oxidative enzymes and
protects human cornea epithelial cells against oxidative damage. Br
J Ophthalmol. 92:992–997. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Reti R, Kwon E, Qiu P, Wheater M and Sosne
G: Thymosin beta4 is cytoprotective in human gingival fibroblasts.
Eur J Oral Sci. 116:424–430. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Badamchian M, Fagarasan MO, Danner RL,
Suffredini AF, Damavandy H and Goldstein AL: Thymosin beta(4)
reduces lethality and down-regulates inflammatory mediators in
endotoxin-induced septic shock. Int Immunopharmacol. 3:1225–1233.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhou T, Huang YX, Song JW and Ma QM:
Thymosin β4 inhibits microglia activation through microRNA 146a in
neonatal rats following hypoxia injury. Neuroreport. 26:1032–1038.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sosne G, Qiu P, Christopherson PL and
Wheater MK: Thymosin beta 4 suppression of corneal NFkappaB: A
potential anti-inflammatory pathway. Exp Eye Res. 84:663–669. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sosne G, Qiu P and Kurpakus-Wheater M:
Thymosin beta 4: A novel corneal wound healing and
anti-inflammatory agent. Clin Ophthalmol. 1:201–207.
2007.PubMed/NCBI
|
|
41
|
Zhang Y, Feurino LW, Zhai Q, Wang H,
Fisher WE, Chen C, Yao Q and Li M: Thymosin beta 4 is overexpressed
in human pancreatic cancer cells and stimulates proinflammatory
cytokine secretion and JNK activation. Cancer Biol Ther. 7:419–423.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Mutchnick MG, Lee HH, Hollander DI, Haynes
GD and Chua DC: Defective in vitro gamma interferon production and
elevated serum immunoreactive thymosin beta 4 levels in patients
with inflammatory bowel disease. Clin Immunol Immunopathol.
47:84–92. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zheng X, Wu SL, Hincapie M and Hancock WS:
Study of the human plasma proteome of rheumatoid arthritis. J
Chromatogr A. 1216:3538–3545. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Choi HM, Lee YA, Yang HI, Yoo MC and Kim
KS: Increased levels of thymosin β4 in synovial fluid of patients
with rheumatoid arthritis: Association of thymosin β4 with other
factors that are involved in inflammation and bone erosion in
joints. Int J Rheum Dis. 14:320–324. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Song R, Choi HM, Yang HI, Yoo MC, Park YB
and Kim KS: Association between serum thymosin β4 levels of
rheumatoid arthritis patients and disease activity and response to
therapy. Clin Rheumatol. 31:1253–1258. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wei M, Duan D, Liu Y, Wang Z and Li Z:
Increased thymosin β4 levels in the serum and SF of knee
osteoarthritis patients correlate with disease severity. Regul
Pept. 185:34–36. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Philp D, Scheremeta B, Sibliss K, Zhou M,
Fine EL, Nguyen M, Wahl L, Hoffman MP and Kleinman HK: Thymosin
beta4 promotes matrix metalloproteinase expression during wound
repair. J Cell Physiol. 208:195–200. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Qiu P, Kurpakus-Wheater M and Sosne G:
Matrix metalloproteinase activity is necessary for thymosin beta 4
promotion of epithelial cell migration. J Cell Physiol.
212:165–173. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Matsuo K, Akasaki Y, Adachi K, Zhang M,
Ishikawa A, Jimi E, Nishihara T and Hosokawa R: Promoting effects
of thymosin β4 on granulation tissue and new bone formation after
tooth extraction in rats. Oral Surg Oral Med Oral Pathol Oral
Radiol. 114:17–26. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Lee SI, Yi JK, Bae WJ, Lee S, Cha HJ and
Kim EC: Thymosin beta-4 suppresses osteoclastic differentiation and
inflammatory responses in human periodontal ligament cells. PLoS
One. 11:e01467082016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Jeong SJ and Jeong MJ: Effect of thymosin
beta4 on the differentiation and mineralization of MC3T3-E1 cell on
a titanium surface. J Nanosci Nanotechnol. 16:1979–1983. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Lee SI, Lee DW, Yun HM, Cha HJ, Bae CH,
Cho ES and Kim EC: Expression of thymosin beta-4 in human
periodontal ligament cells and mouse periodontal tissue and its
role in osteoblastic/cementoblastic differentiation.
Differentiation. 90:16–26. 2015. View Article : Google Scholar : PubMed/NCBI
|
